63 related articles for article (PubMed ID: 15011644)
1. Gene genie. Can gene therapy deliver a better fusion blocker?
Huff B
GMHC Treat Issues; 2003 Dec; 17(12):7. PubMed ID: 15011644
[No Abstract] [Full Text] [Related]
2. An anti-HIV microbicide comes alive.
Lagenaur LA; Berger EA
Proc Natl Acad Sci U S A; 2005 Aug; 102(35):12294-5. PubMed ID: 16118279
[No Abstract] [Full Text] [Related]
3. Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K).
Tolstrup M; Selzer-Plön J; Laursen AL; Bertelsen L; Gerstoft J; Duch M; Pedersen FS; Ostergaard L
AIDS; 2007 Feb; 21(4):519-21. PubMed ID: 17301572
[No Abstract] [Full Text] [Related]
4. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.
Su C; Melby T; DeMasi R; Ravindran P; Heilek-Snyder G
J Clin Virol; 2006 Aug; 36(4):249-57. PubMed ID: 16765082
[TBL] [Abstract][Full Text] [Related]
5. T-1249 development suspended.
Huff B
GMHC Treat Issues; 2003 Dec; 17(12):6. PubMed ID: 15011643
[No Abstract] [Full Text] [Related]
6. Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP).
Gonzalez E; Ballana E; Clotet B; Esté JA
AIDS; 2011 Aug; 25(13):1557-83. PubMed ID: 21572303
[TBL] [Abstract][Full Text] [Related]
7. European Commission approves Fuzeon following FDA approval--first HIV-fusion inhibitor in fight against HIV.
Infection; 2003 Aug; 31(4):7-8. PubMed ID: 14562955
[No Abstract] [Full Text] [Related]
8. Expanded distribution for enfuvirtide.
AIDS Patient Care STDS; 2004 Jun; 18(6):366. PubMed ID: 15384197
[No Abstract] [Full Text] [Related]
9. New drugs show promise in attacking HIV.
Dent Today; 2002 Dec; 21(12):30. PubMed ID: 12572158
[No Abstract] [Full Text] [Related]
10. FDA news. Price criticized for new anti-HIV drug.
AIDS Alert; 2003 May; 18(5):67-8. PubMed ID: 12751460
[TBL] [Abstract][Full Text] [Related]
11. [New drug class blocks virus-cell fusion. HIV not admitted].
MMW Fortschr Med; 2003 Sep; 145(35-36):53. PubMed ID: 14584215
[No Abstract] [Full Text] [Related]
12. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen.
Cabrera C; Marfil S; García E; Martinez-Picado J; Bonjoch A; Bofill M; Moreno S; Ribera E; Domingo P; Clotet B; Ruiz L
AIDS; 2006 Oct; 20(16):2075-80. PubMed ID: 17053353
[TBL] [Abstract][Full Text] [Related]
13. Drug pricing. High price of Fuzeon, other recent drugs sets tough pricing precedent.
AIDS Policy Law; 2005 Jul; 20(14):4. PubMed ID: 16108122
[No Abstract] [Full Text] [Related]
14. US FDA approves new class of HIV therapeutics.
Robertson D
Nat Biotechnol; 2003 May; 21(5):470-1. PubMed ID: 12721558
[No Abstract] [Full Text] [Related]
15. FDA notifications. FDA approves Fuzeon, the first fusion inhibitor.
AIDS Alert; 2003 Jun; 18(6):78-9. PubMed ID: 12866478
[No Abstract] [Full Text] [Related]
16. FDA notifications. Enfuvirtide has new instructions.
AIDS Alert; 2007 Apr; 22(4):44-5. PubMed ID: 17595723
[No Abstract] [Full Text] [Related]
17. Cellular membrane-binding ability of the C-terminal cytoplasmic domain of human immunodeficiency virus type 1 envelope transmembrane protein gp41.
Chen SS; Lee SF; Wang CT
J Virol; 2001 Oct; 75(20):9925-38. PubMed ID: 11559825
[TBL] [Abstract][Full Text] [Related]
18. Tannin inhibits HIV-1 entry by targeting gp41.
Lü L; Liu SW; Jiang SB; Wu SG
Acta Pharmacol Sin; 2004 Feb; 25(2):213-8. PubMed ID: 14769212
[TBL] [Abstract][Full Text] [Related]
19. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
[TBL] [Abstract][Full Text] [Related]
20. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
